Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S

IPH2201 is the third monoclonal antibody developed in collaboration with Novo Nordisk A/S expected to enter clinical trials Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that a European trial application has been filed by Novo Nordisk A/S for IPH2201 (NN8765). This triggered the payment to Innate Pharma of a significant undisclosed milestone. IPH2201 is a humanized antibody generated in the collaboration between Innate Pharma and Novo Nordisk A/S and developed to treat patients with chronic inflammatory and auto-immune diseases. Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗